Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference

Core Viewpoint - Connect Biopharma Holdings Limited is actively participating in the BTIG Virtual Biotechnology Conference, highlighting its focus on transforming care for inflammatory diseases, particularly asthma and COPD [1][3]. Company Overview - Connect Biopharma is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to developing treatments for asthma and COPD [3]. - The company is advancing rademikibart, a next-generation antibody targeting IL-4Rα, currently undergoing global clinical studies for treating acute exacerbations of asthma and COPD [3]. - Connect Biopharma has an exclusive license and collaboration agreement for rademikibart with Simcere in China [3]. Event Details - The management of Connect Biopharma will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on July 29, 2025, at 9:20 a.m. ET [1]. - A live webcast of the event will be available on the company's website, with an archived replay accessible for approximately 90 days post-event [2].